We conducted a non-randomized, open-label clinical trial to assess whether a
psychoneuroimmunology-based intervention enhanced immunity in children with
acute lymphoblastic leukemia undergoing chemotherapy. In total, 16 children (44%
female) received psychoneuroimmunology-based intervention, whereas 12 (50%
female) received health psychoeducation (controls). The primary outcome was
immunity markers, being clinical conditions the secondary outcome.
Psychoneuroimmunology-based intervention increased immune markers (CD8+ T, B,
and natural killer cells, serum immunoglobulin A, and immunoglobulin M) and
quality of life, whereas it shortens the duration of fever and use of
antipyretics, antibiotics, analgesics, and respiratory therapy. Immunity markers
correlated with clinical conditions. Thus, psychoneuroimmunology-based
intervention could reduce hospital cost and increase patient well-being.